SIGA Technologies Inc logo

SIGA Technologies Inc(SIGA)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$2.74
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for SIGA

11/13/2026: SIGA (1-star) is currently NOT-A-BUY. Pass it for now.

SIGA Technologies is a specialized biotechnology firm primarily focused on providing medical countermeasures for biodefense, most notably through its FDA-approved antiviral treatment, TPOXX. Its primary business strength lies in its long-standing, sole-source relationship with the U.S. government for smallpox stockpile requirements. The company’s growth story hinges on expanding TPOXX into international markets and addressing emerging orthopoxvirus threats globally. However, the company faces significant risks, including heavy reliance on a single product, cyclical government procurement cycles, and political funding volatility. This stock may suit investors comfortable with binary outcomes and government-contract-driven performance rather than those seeking consistent, consumer-driven commercial growth or regular dividends.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitThe growth is driven by episodic government contract cycles rather than steady commercial scaling.
Momentum investorStrong fit while signal remains positiveStock price often responds aggressively to news regarding major government contracts or health emergency headlines.
Value investorMixed fitValuation is often tied to the perceived probability of future government contract awards rather than traditional earnings multiples.
Dividend investorWeak fitThe company does not provide a predictable, recurring dividend stream.
Low-risk investorWeak fitHigh revenue concentration and dependence on political/regulatory outcomes create significant binary risk.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock is subject to sharp movements based on government procurement announcements.
Valuation riskMediumValuation is sensitive to contract renewal timelines and political funding cycles.
Competition risk (government contracting)MediumThe sector relies on a limited number of government buyers, creating high dependency risk.
Business qualityMediumWhile the product is essential, the single-product reliance limits long-term franchise quality.
Dividend incomeLow / noneThe company does not offer regular dividend income for conservative investors.
Execution riskMediumSuccessfully fulfilling complex government contracts requires precision and regulatory adherence.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 196.88M USD
Price to earnings Ratio 274
1Y Target Price 17.53
Price to earnings Ratio 274
1Y Target Price 17.53
Volume (30-day avg) 534.2K shares
Beta 1.04
52 Weeks Range 2.71 - 6.29
Updated Date 11/14/2026
52 Weeks Range 2.71 - 6.29
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) 0.01

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Drug Manufacturers - Specialty & Generic

BUY participation
66.7%
Active BUY / eligible
8 / 12
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Moderately Choppy
PRICE STABILITY

Moderately Choppy

The stock has experienced noticeable price swings while retaining some directional structure.

Analysis of Past Performance

Type Stock
Historic Profit -19.3%
Avg. Invested days 31
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
SIGA receives a 4-star rating, supported by strong unit economics, and solid company fundamentals. The rating is constrained by weak price momentum.

Company Fundamentals

★★★★★
SIGA has solid overall fundamentals (4 stars), with solid financial health, soft growth momentum, and solid ownership. In FY2025 versus FY2024, strong cash generation (FCF margin 45.6%) and strong profitability (net margin 24.6%) are partially offset by negative earnings growth (-60.7%), negative revenue growth (-31.8%).

Financial Health Rating

★★★★★
SIGA's financial health is supported by strong liquidity, including working-capital and asset support (WC/assets 88.8%). Operating efficiency is solid (4 stars), which helps explain the 4-star overall score.

Growth Momentum Score

★★★★★
SIGA's growth profile is soft, with the least-weak measure being free-cash-flow growth at -11.5% FY2025 versus FY2024. By comparison, while revenue growth (-31.8%, negative) and earnings growth (-60.7%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 47.3% and approximately 57.2% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 42.80% supports management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 5.83%
AltraVue Capital, LLC 3.24%
Dimensional Fund Advisors, Inc. 2.80%
Vanguard Capital Management, LLC 2.38%
American Century Companies Inc 2.10%

Unit Economics (Per $1K Revenue)

★★★★★
SIGA generates approximately $686 of gross profit, $251 of operating income, and $456 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Strong margins, cash conversion, and capital efficiency support the rating.

Economic Dimensions

★★★★★
Effective Tax Rate: 23.36%

Quantitative Style Profile

★★★★★
SIGA has a liquid profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Small / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
U.S. Government ContractingProcurement of TPOXX for the Strategic National Stockpile.The vast majority of revenue comes from large, infrequent orders from the U.S. government.
International/Commercial SalesTPOXX sales to international governments and health organizations.This is a secondary growth area aimed at diversifying revenue away from the U.S. government.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE 274
Forward PE 2.54
Enterprise Value 80.78M
Price to Sales(TTM) 3.76
Enterprise Value 80.78M
Price to Sales(TTM) 3.76
Enterprise Value to Revenue 1.54
Enterprise Value to EBITDA 3.71
Shares Outstanding 71.86M
Shares Floating 41.12M
Shares Outstanding 71.86M
Shares Floating 41.12M
Percent Insiders 42.8
Percent Institutions 47.26

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.